Cuál es el precio por Scilex Holding Company (SCLX)

Precio por Scilex Holding Company (SCLX) es de$5.61

Cuál es la capitalización de mercado por Scilex Holding Company (SCLX)

Capitalización de mercado por Scilex Holding Company (SCLX) es $47.65M

Ingresos de Scilex Holding Company (SCLX)

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Año	Ingresos	Cambiar
Not enough data for the provided dates.

Año

Ingresos

Cambiar

Not enough data for the provided dates.

Empresa	Ingresos	Diferencia de ingresos	País
Eli Lilly and Company LLY.US	$79.67B	-	US
Johnson & Johnson JNJ.US	$97.93B	-	US
AbbVie Inc. ABBV.US	$64.39B	-	US
Roche Holding AG RO.SW	$77.52B	-	CH
Merck & Co., Inc. MRK.US	$66.40B	-	US

Empresa

Ingresos

Diferencia de ingresos

País